Marc Hoffman, MD, was placed as the chief science and medical officer of Rockwell Medical, Inc. in Bergen County, New Jersey. Founded in the 1990s, Rockwell is a fully integrated biopharmaceutical and medical device company targeting end-stage renal disease, oncology, and total parenteral nutrition. The company has achieved the first and only FDA approval of a therapeutic indicated to treat potentially anemic hemodialysis patients and is in the process of launching this therapeutic into the U.S. market; further, Rockwell has received patent protection in numerous countries, including in the four largest markets worldwide relative to its lead targeted therapeutic area. In the new CSO/CMO role, Dr. Hoffman holds both chief medical officer and R&D responsibilities, providing leadership and direction for the company's pipeline of clinical development programs in drug development and for the strategy, direction, and execution of its clinical development plans.
Dr. Hoffman comes to Rockwell from Celerion. As chief medical officer, he was directly involved in defining and implementing the overall business strategy and direction of the organization; providing medical oversight, expertise, and leadership to support early clinical research studies at Celerion's clinics globally; and holding operational responsibility for the oversight and expansion of clinical operations focused on early clinical research (phase I/II) performed outside of Celerion clinics in North America.
Previously, Dr. Hoffman served as the chief medical officer of Chiltern International and its subsidiary Theorem Clinical Research; as vice president of medical and scientific affairs for Covance; as vice president of global medical affairs and product safety for Hospira, Inc.; in progressively responsible roles with Baxter Healthcare Corporation in clinical research, medical affairs, and global regulatory affairs; and as the president of MEDEX. He began his career as a research associate in Europe after earning his bachelor's degree in psychology from Emory University and his MD from American University of the Caribbean School of Medicine. Dr. Hoffman also holds a Diploma of Pharmaceutical Medicine from the Royal College of Medicine at the University of Wales in the UK.